Sugi Predict

Sugi Predict / Compounds / SCHEMBL16094239

SCHEMBL16094239

SCHEMBL16094239

Cc1ccc(N)cc1-c1cc(F)nc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.43
▸ PLA2G7 Q13093 1/20 0.43
▸ CASP1 P29466 4/20 0.42
▸ ABL1 P00519 2/20 0.41
▸ TSHR P16473 4/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ PDE10A Q9Y233 1/20 0.39
▸ RAF1 P04049 1/20 0.39
▸ KDM4E B2RXH2 5/20 0.39
▸ MAPT P10636 4/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ GAA P10253 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ RECQL P46063 2/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ SENP8 Q96LD8 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ SENP6 Q9GZR1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30405473 0.89 PLA2G7 (0.45) ALDH1A1PLA2G7CASP1ABL1TSHR
SCHEMBL25261605 0.89 PLA2G7 (0.45) ALDH1A1PLA2G7CASP1ABL1TSHR
SCHEMBL16095011 0.78 RAF1 (0.55) ALDH1A1CYP3A4RAF1KDM4ESMN1; SMN2
SCHEMBL31205642 0.78 RAF1 (0.55) ALDH1A1CYP3A4RAF1KDM4ESMN1; SMN2
SCHEMBL17595012 0.78 PLA2G7 (0.51) ALDH1A1PLA2G7CASP1ABL1TSHR
SCHEMBL31312426 0.78 PLA2G7 (0.51) ALDH1A1PLA2G7CASP1ABL1TSHR
SCHEMBL20021943 0.77 ALDH1A1 (0.46) ALDH1A1PLA2G7CASP1ABL1TSHR
SCHEMBL3783964 0.76 ALDH1A1 (0.54) ALDH1A1PLA2G7CASP1TSHRCYP3A4
SCHEMBL31607621 0.75 PLA2G7 (0.65) ALDH1A1PLA2G7CASP1TSHRCYP3A4
SCHEMBL30092397 0.75 PLA2G7 (0.65) ALDH1A1PLA2G7CASP1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 — — US disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 — — US disclosed
WO-2023108103-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 — — WO disclosed
US-20220135539-A1 BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF Eternity Bioscience Inc. 2022-05-05 — — US disclosed
US-20220135539-A1 BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF Eternity Bioscience Inc. 2022-05-05 — — US disclosed
CN-108467369-B Biaryl amide compounds as kinase inhibitors 诺华股份有限公司 2021-08-20 — — CN disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
EP-3299367-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2018-03-28 — — EP disclosed
US-9573969-B2 Compounds and compositions as kinase inhibitors NOVARTIS AG (CH) 2017-02-21 — — US disclosed
US-9573969-B2 Compounds and compositions as kinase inhibitors NOVARTIS AG (CH) 2017-02-21 — — US disclosed
WO-2016038581-A1 COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-17 — — WO disclosed
US-20160075727-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-17 — — US disclosed
US-20160075727-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-17 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
EP-2970216-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2016-01-20 — — EP disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160075727-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS RAF1, BRAF, ARAF ALDH1A1 2584/4885PLA2G7 1448/4885CASP1 1939/4885
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF ALDH1A1 2049/4885PLA2G7 2531/4885CASP1 3475/4885
US-20220135539-A1 BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF BRAF, NRAS, RAF1 ALDH1A1 1618/4885PLA2G7 1094/4885CASP1 3871/4885
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS ALDH1A1 1592/4885PLA2G7 1184/4885CASP1 2982/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS ALDH1A1 1592/4885PLA2G7 1184/4885CASP1 2982/4885
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS ALDH1A1 1592/4885PLA2G7 1184/4885CASP1 2982/4885
US-10245267-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS ALDH1A1 1592/4885PLA2G7 1184/4885CASP1 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.